Home/Pipeline/TD139

TD139

Idiopathic Pulmonary Fibrosis (IPF)

Phase 2/3DiscontinuedNCT03832946 (GALACTIC-1)

Key Facts

Indication

Idiopathic Pulmonary Fibrosis (IPF)

Phase

Phase 2/3

Status

Discontinued

Company

Galecto

About Galecto

Galecto's mission is to develop transformative therapeutics for fibrosis, inflammation, and cancer by selectively inhibiting galectin proteins, central mediators of these disease processes. Its key achievement is advancing its lead oral galectin-3 inhibitor, GB1211, into Phase 2 trials for liver fibrosis and Phase 1b/2 for oncology combinations. The company's strategy is to generate robust clinical proof-of-concept data in these serious conditions to unlock significant value. Galecto operates as a focused, platform-based entity, aiming to demonstrate the broad therapeutic potential of its galectin-targeting approach.

View full company profile

Therapeutic Areas

Fibrosis Oncology

Other Idiopathic Pulmonary Fibrosis (IPF) Drugs

Drug	Company	Phase	Status
OATD-01	Molecure	Phase II	Active, recruiting
FP-020 (BMS-986235)	Foresee Pharmaceuticals	Phase 2	Active
Buloxibutid (C21)	Vicore Pharma	Phase 2b	Active, Now Enrolling
AP02	Avalyn Pharmaceuticals	Phase 2	Active
Gento-Fibrose Pulmonaire Program	Genoscience Pharma	Preclinical	Active
SM001 (alidornase/Tigerase)	SarcoMed USA	Research	Active
NLM-001	Nelum Pharma	Phase 1	Active
GNS-3545 (ROCK2 Inhibitor)	Genosco	Phase 1	Active
TG2 Inhibitor Program	Isterian Biotech	Preclinical	Active
Taladegib (ENV-101)	Endeavor BioMedicines	Phase 2b	Active
CAL101	Calluna Pharma	Phase 2	Active
NVP-13	Velvio	Pre-clinical	Active